SDS Biotech achieved sales of 4,960 million yen in Q2 FY2018

Net sales of SDS Biotech for the second quarter of the fiscal year ending March 2019, were 4,960 million yen (USD 43.8 million at the current rate), operating income was 301 million yen (USD 2.7 million), ordinary income was 306 million yen (USD 2.7 million) and net income came to 63 million yen (USD 55,600). 

 

The company did not analyze figures in the same period the previous year and changes compared to the same period the previous year because they transitioned to non-consolidated accounting from the settlement of accounts for the fiscal year ended March 31, 2018.

 

According to the company, demand for Daconil-related products (technical and formulations), the mainstay products, has continued to grow globally, the company cannot respond to the demand due to the effects of the fire incident at Yokohama Works, which occurred in February this year.

 

Net sales of fungicide sector for the period under review were 1,050 million yen (USD 9.3 million). This mainly products were Daconill products (technical and formulation). 

 

Net sales of paddy herbicide sector were 1,564 million yen (USD 13.8 million). The main products were Diamuron technical, Benzobicyclon technical and Cafenstrole technical for Japanese market. 

 

Net sales of Greenery-related products were 1,208 million yen (USD 10.7 million). The main products were Karbutilate products (technical and formulation) for Japanese market, and Dacthal technical for overseas market. 

 

Net sales of insecticides were 338 million yen (USD 3 million). The main products were D-D products and biological product (Tune-up WDG) for Japanese market. 

 

Net sales of other products were 799 million yen. The mainly products were Daconil raw material.